Glaukos (NYSE:GKOS) Bolsa

GLAUKOS CORP

Glaukos

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

Glaukos Corp

Morgan Stanley analyst Patrick Wood maintains Glaukos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GKOS#NYSE">GKOS</a>) with a Underweight and lowers the price target from $110 to $72.

News

Price Target

Analyst Ratings

GKOS

Morgan Stanley Maintains Underweight on Glaukos, Lowers Price Target to $72

In the latest quarter, 11 analysts provided ratings for Glaukos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GKOS#NYSE">GKOS</a>), showcasing a mix of bullish and bearish perspectives.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Glaukos, revealing an average target of $143.82, a high estimate of $200.00, and a low estimate of $86.00. A decline of 10.26% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2025/1746219740_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
A clear picture of Glaukos's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mason Carrico</td>
<td>Stephens &amp; Co.</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$115.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Thomas Stephan</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$115.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$135.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Larry Biegelsen</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$86.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>David Saxon</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$115.00</td>
<td>$176.00</td>
</tr>
<tr>
<td>Anthony Petrone</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$175.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Matt O'Brien</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$165.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$140.00</td>
<td>$185.00</td>
</tr>
<tr>
<td>Larry Biegelsen</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$160.00</td>
<td>$153.00</td>
</tr>
<tr>
<td>David Saxon</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$176.00</td>
<td>$149.00</td>
</tr>
<tr>
<td>Anthony Petrone</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$200.00</td>
<td>$140.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Glaukos. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Glaukos compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Glaukos's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Glaukos's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/GKOS/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Glaukos analyst ratings.</a>
<h2>About Glaukos</h2>
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.
<h3>Glaukos: A Financial Overview</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining Glaukos's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 1.1% as of 31 March, 2025, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of -17.01%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Glaukos's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -2.37%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Glaukos's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -1.87%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Glaukos's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.14.
<h2>The Basics of Analyst Ratings</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What 11 Analyst Ratings Have To Say About Glaukos

Stephens &amp; Co. analyst Mason Carrico maintains Glaukos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GKOS#NYSE">GKOS</a>) with a Overweight and lowers the price target from $140 to $115.

Stephens & Co. Maintains Overweight on Glaukos, Lowers Price Target to $115

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Baird analyst Andrew Wittmann downgraded the rating for Parsons Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSN#NYSE">PSN</a>) from Outperform to Neutral and lowered the price target from $72 to $69. Parsons shares closed at $66.86 on Wednesday. <a href="https://www.benzinga.com/quote/PSN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wells Fargo analyst Larry Biegelsen downgraded Glaukos Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GKOS#NYSE">GKOS</a>) from Overweight to Equal-Weight and lowered the price target from $160 to $86. Glaukos shares closed at $94.25 on Wednesday. <a href="https://www.benzinga.com/quote/GKOS/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wells Fargo analyst Yanan Zhu downgraded the rating for Regulus Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGLS#NASDAQ">RGLS</a>) from Overweight to Equal-Weight and announced a $9 price target. Regulus Therapeutics shares closed at $7.98 on Wednesday. <a href="https://www.benzinga.com/quote/RGLS/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying PSN stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="576" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/01133919/image-12-1024x576.png" alt="" class="wp-image-897568" style="width:583px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/01133919/image-12-1024x576.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/01133919/image-12-300x169.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/01133919/image-12-768x432.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/01133919/image-12.png 1128w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/05/45135511/how-to-earn-500-a-month-from-apple-stock-ahead-of-q2-earnings">How To Earn $500 A Month From Apple Stock Ahead Of Q2 Earnings</a> </li>
</ul>
Photo via Shutterstock

Downgrades

Markets

Trading Ideas

RGLS

This Parsons Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Thursday

Stifel analyst Thomas Stephan maintains Glaukos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GKOS#NYSE">GKOS</a>) with a Buy and lowers the price target from $140 to $115.

Stifel Maintains Buy on Glaukos, Lowers Price Target to $115

Truist Securities analyst Richard Newitter reiterates Glaukos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GKOS#NYSE">GKOS</a>) with a Buy and lowers the price target from $140 to $135.

Reiteration

Truist Securities Reiterates Buy on Glaukos, Lowers Price Target to $135

Wells Fargo analyst Larry Biegelsen downgrades Glaukos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GKOS#NYSE">GKOS</a>) from Overweight to Equal-Weight and lowers the price target from $160 to $86.

Wells Fargo Downgrades Glaukos to Equal-Weight, Lowers Price Target to $86

WIIM

Glaukos shares are trading lower after the company reported Q1 financial results. Additionally, Needham cut its price target on the stock from $176 to $115.

Needham analyst David Saxon maintains Glaukos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GKOS#NYSE">GKOS</a>) with a Buy and lowers the price target from $176 to $115.

Needham Maintains Buy on Glaukos, Lowers Price Target to $115

Glaukos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GKOS#NYSE">GKOS</a>) affirms FY2025 sales outlook from $475.00 million-$485.00 million to $475.00 million-$485.00 million vs $480.63 million estimate.

Guidance

Glaukos Affirms FY2025 Sales Guidance of $475.00M-$485.00M vs $480.63M Est

Glaukos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GKOS#NYSE">GKOS</a>) reported quarterly losses of $(0.22) per share which beat the analyst consensus estimate of $(0.35) by 37.14 percent. This is a 68.57 percent increase over losses of $(0.70) per share from the same period last year. The company reported quarterly sales of $106.66 million which beat the analyst consensus estimate of $102.50 million by 4.06 percent. This is a 24.58 percent increase over sales of $85.62 million the same period last year.

Earnings

Earnings Beats

Glaukos Q1 Adj. EPS $(0.22) Beats $(0.35) Estimate, Sales $106.66M Beat $102.50M Estimate

AEIS

ALGN

ALKT

AMCR

ANSS

ARAY

ATNI

AWRE

BLCO

BLFY

BLKB

BXMT

CACC

CAKE

CDNA

CFLT

CGNX

CHEF

CHRW

CLMB

CMPR

CNMD

CNXN

COCO

COKE

CPSH

CSLR

CSTM

CTOS

CTSH

CVEO

CWAN

CWEN

DFIN

EBAY

ENVX

EQIX

EQNR

ETSY

EXTR

FCPT

FFWM

FINW

FMBH

FORM

FTAI

GEHC

GNRC

GRBK

GRMN

GTES

Earnings Scheduled For April 30, 2025

In the preceding three months, 7 analysts have released ratings for Glaukos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GKOS#NYSE">GKOS</a>), presenting a wide array of perspectives from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Glaukos, revealing an average target of $170.86, a high estimate of $200.00, and a low estimate of $140.00. This upward trend is apparent, with the current average reflecting a 4.27% increase from the previous average price target of $163.86.
<img src="https://www.benzinga.com/files/images/story/2025/1744840876_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Glaukos. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Anthony Petrone &#x7C;Mizuho &#x7C;Lowers &#x7C;Outperform &#x7C; $175.00&#x7C;$200.00 &#x7C; 
&#x7C;Matt O'Brien &#x7C;Piper Sandler &#x7C;Lowers &#x7C;Overweight &#x7C; $165.00&#x7C;$180.00 &#x7C; 
&#x7C;Richard Newitter &#x7C;Truist Securities &#x7C;Lowers &#x7C;Buy &#x7C; $140.00&#x7C;$185.00 &#x7C; 
&#x7C;Larry Biegelsen &#x7C;Wells Fargo &#x7C;Raises &#x7C;Overweight &#x7C; $160.00&#x7C;$153.00 &#x7C; 
&#x7C;David Saxon &#x7C;Needham &#x7C;Raises &#x7C;Buy &#x7C; $176.00&#x7C;$149.00 &#x7C; 
&#x7C;Anthony Petrone &#x7C;Mizuho &#x7C;Raises &#x7C;Outperform &#x7C; $200.00&#x7C;$140.00 &#x7C; 
&#x7C;Matt O'Brien &#x7C;Piper Sandler &#x7C;Raises &#x7C;Overweight &#x7C; $180.00&#x7C;$140.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Glaukos. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Glaukos compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Glaukos's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/GKOS/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Glaukos analyst ratings.</a>
<h2>Discovering Glaukos: A Closer Look</h2>
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.
<h3>Glaukos: Financial Performance Dissected</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Over the 3M period, Glaukos showcased positive performance, achieving a revenue growth rate of 28.09% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Glaukos's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -31.83%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -4.68%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Glaukos's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -3.53%, the company may face hurdles in achieving optimal financial returns.
Debt Management: With a below-average debt-to-equity ratio of 0.13, Glaukos adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>What Are Analyst Ratings?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Forecasting The Future: 7 Analyst Projections For Glaukos

Mizuho analyst Anthony Petrone maintains Glaukos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GKOS#NYSE">GKOS</a>) with a Outperform and lowers the price target from $200 to $175.

Mizuho Maintains Outperform on Glaukos, Lowers Price Target to $175

Piper Sandler analyst Matt O'Brien maintains Glaukos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GKOS#NYSE">GKOS</a>) with a Overweight and lowers the price target from $180 to $165.

Piper Sandler Maintains Overweight on Glaukos, Lowers Price Target to $165

Truist Securities analyst Richard Newitter maintains Glaukos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GKOS#NYSE">GKOS</a>) with a Buy and lowers the price target from $185 to $140.

Truist Securities Maintains Buy on Glaukos, Lowers Price Target to $140

Glaukos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GKOS#NYSE">GKOS</a>) has outperformed the market over the past 5 years by 10.4% on an annualized basis producing an average annual return of 27.01%. Currently, Glaukos has a market capitalization of $5.83 billion. 
Buying $1000 In GKOS: If an investor had bought $1000 of GKOS stock 5 years ago, it would be worth $3,057.55 today based on a price of $103.15 for GKOS at the time of writing.
<h3>Glaukos's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1743200109_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Glaukos Stock In The Last 5 Years

Inspire by RadiusXR is the only commercially available wearable vision diagnostic system that combines visual field testing correlated to the clinical standard with proven performance, onboard patient education, and data-driven intelligence to support more informed clinical decisions. Six ounces and purpose-built for future expansion, Inspire extends beyond traditional diagnostics to support testing for other chronic and systemic conditions.

Health Care

Contracts

General

Topcon Healthcare, RadiusXR, And Glaukos Announced A New Collaboration And The Launch Of RadiusXR's New Wearable Vision Testing Platform, Inspire

Glaukos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GKOS#NYSE">GKOS</a>) has outperformed the market over the past 5 years by 8.36% on an annualized basis producing an average annual return of 23.52%. Currently, Glaukos has a market capitalization of $6.95 billion. 
Buying $100 In GKOS: If an investor had bought $100 of GKOS stock 5 years ago, it would be worth $205.69 today based on a price of $126.07 for GKOS at the time of writing.
<h3>Glaukos's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1740408314_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $100 Invested In Glaukos 5 Years Ago Would Be Worth Today

On Monday, Glaukos Corporation&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GKOS#NYSE">GKOS</a>) received the &#8220;Day 74&#8221; notification from the U.S. Food and Drug Administration (FDA) acknowledging the previously submitted New Drug Application (NDA) for Epioxa (Epi-on), its next-gen corneal cross-linking iLink therapy for keratoconus, a sight-threatening corneal disease, is sufficiently complete to <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/b43908675/glaukos-announces-fda-acceptance-of-nda-submission-for-epioxa" rel="noreferrer noopener">permit a substantive review</a>.
The Prescription Drug User Fee Act goal date for the completion of the FDA&#8217;s review of the Epioxa NDA is set for Oct. 20, 2025.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/health-care/25/02/43883818/glaukos-delivers-mixed-q4-results-analyst-sees-growing-investor-interest-during-transition" rel="noreferrer noopener">Glaukos Delivers Mixed Q4 Results, Analyst Sees Growing Investor Interest During Transition</a>
&#8220;The acceptance of the Epioxa NDA represents another important step in being able to provide keratoconus patients and the ophthalmic community with the first FDA-approved, non-invasive corneal cross-linking drug therapy that does not require removal of the corneal epithelium, the outermost layer of the front of the eye,&#8221; said Glaukos CEO Thomas Burns.
The NDA submission includes data from two Phase 3 pivotal Epioxa trials, which achieved the pre-specified primary efficacy endpoints and demonstrated favorable tolerability and safety profiles.
Glaukos&#8217; corneal cross-linking iLink therapies use proprietary, bio-activated drug formulations designed to strengthen corneal tissue and halt the progression of keratoconus.
Glaukos&#8217; first-generation iLink therapy, known as Photrexa, or&nbsp;Epi-off, is the first and only FDA-approved therapy that has been shown to slow or halt disease progression.
Epioxa utilizes a proprietary, novel drug formulation designed to penetrate the epithelial layer of the cornea, a stronger UV-A irradiation protocol, and supplemental oxygen to enhance cross-linking.
Price Action: GKOS stock is up 25% at $157.36&nbsp;during the premarket session on last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43890152/insulets-strong-q4-highlights-surging-omnipod-demand-and-growth-potential-analyst-sees-continued-growth-in-2025" target="_blank" rel="noreferrer noopener">Insulet&#8217;s Strong Q4 Highlights Surging Omnipod Demand And Growth Potential: Analyst</a></li>
</ul>
Image: Shutterstock

Movers

FDA Sets Decision Date For Glaukos' Keratoconus Treatment Without The Need Of Surgery

Press Releases

Glaukos Submits New Drug Application to U.S. FDA for Epioxa™

Glaukos Announces Positive Clinical Updates for its iDose® Sustained-Release Procedural Pharmaceutical Platform

Glaukos to Release Fourth Quarter and Full Year 2024 Financial Results after Market Close on February 20

Glaukos Announces Fourth Quarter and Full Year 2024 Financial Results

Glaukos Announces FDA Acceptance of NDA Submission for Epioxa™

RadiusXR and Glaukos Corporation Announce a New Collaboration With Topcon Healthcare, Inc. and the Launch of Inspire®: A Next-Generation Visual Field Solution

Glaukos to Release First Quarter 2025 Financial Results after Market Close on April 30

Glaukos Announces the Release of its 2024 Sustainability Report

Glaukos to Present Multiple Scientific Abstracts at the 2025 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting

Comments

Glaukos

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL